 | |
| Clinical data | |
|---|---|
| Other names | Nabutam, benzopyranoperidine, SP-106, Abbott 40656 |
| Drug class | Cannabinoid |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C35H52N2O3 |
| Molar mass | 548.812 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nabitan (nabutam,benzopyranoperidine,SP-106,Abbott 40656) is asyntheticcannabinoidanalog ofdronabinol (Δ9-tetrahydrocannabinol) anddimethylheptylpyran.[1] It exhibitsantiemetic andanalgesic effects, most likely by binding to and activating theCB1 andCB2cannabinoid receptors, and reducedintraocular pressure in animal tests, making it potentially useful in the treatment ofglaucoma.[2]
Nabitan has the advantage of being water-soluble, unlike most cannabinoid derivatives, and was researched for potential use as an analgesic orsedative,[3] although it was never developed for clinical use and is not currently used in medicine, asdronabinol ornabilone were felt to be more useful. However, it is sometimes used in research into the potential therapeutic applications of cannabinoids.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
